DMARDs — Conventional and Biologic

Disease-modifying antirheumatic drugs (DMARDs) are a heterogeneous class of immunosuppressive agents that reduce signs and symptoms of inflammatory arthritis while slowing or halting structural joint damage progression. DMARDs represent a fundamental shift in rheumatologic therapy from purely symptomatic management to disease-modifying approaches, fundamentally improving outcomes in rheumatoid arthritis (RA), seronegative spondyloarthropathies, and other inflammatory conditions. The prevalence of RA affecting approximately 0.5–1% of the population globally, with higher incidence in women, underscores the widespread clinical importance of DMARD therapy. The introduction of conventional synthetic DMARDs in the 1980s and biologic DMARDs beginning in the late 1990s has transformed RA from a relentlessly progressive disabling disease into one with achievable remission or low disease activity in the majority of treated patients. Understanding DMARD mechanisms, efficacy, toxicity profiles, and appropriate sequencing is essential for board preparation and clinical practice, as inappropriate therapy selection or monitoring can result in preventable morbidity including opportunistic infections and malignancy.

DMARDs function through distinct mechanisms targeting various components of the autoimmune and inflammatory cascade that drives rheumatologic disease. Understanding how these drugs interrupt pathogenic pathways provides insight into their clinical efficacy, toxicity, and appropriate use:

In rheumatoid arthritis and other autoimmune conditions, autoreactive CD4+ T cells recognize arthritogenic peptides presented via HLA-DR molecules on professional antigen-presenting cells. This recognition activates T cells through interaction of the T cell receptor (TCR) complex with HLA-peptide complexes and crucial co-stimulatory signals (CD28 interaction with B7 molecules on APCs). Methotrexate (MTX), the cornerstone conventional DMARD, acts as a folate antagonist inhibiting dihydrofolate reductase, depleting tetrahydrofolate cofactors essential for nucleotide synthesis and purine metabolism. This reduces lymphocyte proliferation particularly affecting T cells, which are dependent on de novo purine synthesis. Additionally, MTX accumulates as polyglutamates intracellularly, amplifying these effects. At therapeutic doses used in RA (15–25 mg weekly), MTX achieves selective immunosuppression while sparing most rapidly dividing cells due to enhanced cellular uptake via reduced folate carriers highly expressed on lymphocytes. MTX also increases adenosine release, which activates adenosine receptors on T cells and macrophages, producing anti-inflammatory effects. Biologic agents like abatacept directly block co-stimulation by providing a recombinant fusion protein (CTLA4-Ig) that competitively binds B7 molecules on APCs, preventing CD28 engagement on T cells and effectively silencing T cell activation signals at their source.

B cells contribute to pathogenic autoimmunity through both antibody production (particularly rheumatoid factor and anti-CCP antibodies driving immune complex formation and complement activation) and through cytokine production and antigen presentation functions. Rituximab, the prototype anti-CD20 monoclonal antibody, binds CD20 surface antigen expressed on pre-B cells through mature B cells but not on plasma cells or B cell precursors. This binding triggers B cell destruction through antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells and macrophages, complement-dependent cytotoxicity (CDC), and direct induction of apoptosis through CD20 cross-linking. Rituximab administration results in profound B cell depletion within 2–4 weeks, with B cell recovery occurring over 6–9 months as new B cells derive from surviving precursors. This B cell depletion reduces both pathogenic autoantibody production and pro-inflammatory cytokine secretion by B cells. Belimumab, a BAFF antagonist, blocks B cell activating factor (BAFF), a TNF family member essential for B cell survival and differentiation into plasma cells, achieving a more selective anti-B cell effect while theoretically preserving protective humoral immunity longer. The selectivity of B cell targeting for RA and SLE reflects these conditions' prominent pathogenic B cell contributions.

Tumor necrosis factor alpha (TNF-α) is a cardinal pro-inflammatory cytokine produced primarily by activated macrophages and T cells in inflamed synovial tissue. TNF-α acts on TNF receptors 1 and 2 (TNFR1 and TNFR2) expressed on multiple cell types, triggering intracellular signaling cascades including nuclear factor-κB (NF-κB) activation that drives transcription of additional pro-inflammatory cytokines (IL-6, IL-8, TNF-α itself), chemokines recruiting immune cells to joints, adhesion molecules facilitating leukocyte extravasation, and matrix metalloproteinases (MMPs) directly destroying cartilage and bone. TNF-α also stimulates osteoclast differentiation through RANKL upregulation, explaining its central role in bone destruction in RA. TNF inhibitors reduce synovial TNF-α levels dramatically through two distinct mechanisms: infliximab and adalimumab are monoclonal antibodies that directly bind circulating TNF-α, sequestering it and preventing receptor engagement while also triggering complement-mediated destruction of TNF-producing cells; etanercept, a soluble TNF receptor-Fc fusion protein, acts as a decoy receptor competitively binding TNF-α before it reaches membrane-bound TNF receptors. These agents reduce not only direct TNF-α signaling but also downstream inflammatory amplification loops, as TNF-α-mediated NF-κB activation in synovial fibroblasts drives IL-6 production, which itself sustains inflammation. TNF inhibition reduces recruitment of effector T cells and macrophages to synovium, promotes regulatory T cell (Treg) expansion through IL-2 signaling, and decreases angiogenesis, all contributing to reduced disease activity.

Interleukin-6 (IL-6) is a pleiotropic cytokine produced by synovial fibroblasts, macrophages, and endothelial cells in RA, exerting pro-inflammatory effects through both classical signaling (membrane-bound IL-6 receptor on responsive cells) and trans-signaling (soluble IL-6 receptor allowing signaling in cells lacking membrane IL-6R). IL-6 drives T cell differentiation toward pro-inflammatory Th17 cells while suppressing regulatory T cell development, amplifies B cell maturation and autoantibody production, stimulates acute phase protein production by hepatocytes (explaining CRP and ESR elevation), and promotes osteoclastogenesis. Tocilizumab (anti-IL-6 receptor monoclonal antibody) and sarilumab block membrane-bound and soluble IL-6 receptors, preventing both classical and trans-signaling. Tocilizumab produces rapid CRP normalization and reduction in systemic inflammatory markers, though paradoxically IL-6 levels often rise due to loss of negative feedback, distinguishing IL-6 inhibition from TNF inhibition. IL-6 inhibition particularly targets B cell dysregulation and acute phase response while preserving some TNF-α signaling.

Janus kinases (JAKs) are intracellular tyrosine kinases that phosphorylate signal transducers and activators of transcription (STATs) in response to cytokine receptor engagement. Multiple pro-inflammatory cytokines critical to RA pathogenesis signal through JAK-STAT pathways, including interferons (IFN-α, IFN-β, IFN-γ), interleukins (IL-2, IL-4, IL-6, IL-7, IL-12, IL-15, IL-17, IL-21, IL-23), and growth factors (GM-CSF). Conventional JAK inhibitors like tofacitinib (pan-JAK inhibitor) and newer selective JAK inhibitors like baricitinib (JAK1/JAK2 selective) and upadacitinib (JAK1 selective) block phosphorylation of downstream STAT proteins, preventing their nuclear translocation and transcription of pro-inflammatory genes. JAK inhibition is particularly effective for IL-6 and IL-12/IL-23 signaling (critical for Th17 differentiation), TNF-α signaling amplification through JAK-dependent mechanisms, and Type I IFN signaling important in SLE. The broad spectrum of JAK inhibition provides rapid anti-inflammatory effects visible within days to weeks, explaining their popularity, though this breadth also accounts for immunosuppressive effects and side effects.

Sulfasalazine, a prodrug cleaved by colonic bacteria into 5-aminosalicylic acid and sulfapyridine, modulates NF-κB signaling and reduces IL-6 and TNF-α production through incompletely understood mechanisms, with sulfapyridine (not the 5-ASA component) accounting for antirheumatic efficacy. Leflunomide is a prodrug converted to an active metabolite A77 1726 that inhibits dihydroorotate dehydrogenase, a key enzyme in de novo pyrimidine synthesis, selectively suppressing lymphocyte proliferation while minimally affecting nucleotide salvage pathways used by other cells. Hydroxychloroquine, primarily used in SLE and less potent in RA, raises lysosomal pH inhibiting antigen processing, reduces TLR9 signaling in plasmacytoid dendritic cells, and interferes with autophagy, collectively reducing autoimmune activation though by poorly defined mechanisms. These conventional synthetic DMARDs collectively shift the T cell population toward Treg phenotypes while reducing Th1 and Th17 differentiation.

DMARDs are therapeutically indicated for inflammatory conditions characterized by autoimmune pathology rather than for specific etiologic agents. Understanding the disease contexts requiring DMARDs clarifies indications:

RA is a systemic autoimmune condition of unknown ultimate etiology (though genetic predisposition, environmental triggers including smoking and infections, and loss of immune tolerance converge) characterized by symmetric polyarthritis primarily affecting small joints. The pathogenesis involves breakdown of immune tolerance with generation of autoreactive CD4+ T cells and B cells producing rheumatoid factor and anti-CCP antibodies. Genetic risk factors include HLA-DR alleles encoding shared epitope (particularly HLA-DRB1*04 and *01 alleles) conveying 3–5 fold increased RA risk, and non-HLA genetic loci (PTPN22, STAT4, TRAF1/C5, others) identified through genome-wide association studies. Environmental risk factors include cigarette smoking (increases RA risk 2–3 fold, particularly in ACPA-positive disease, possibly through PAD4-mediated citrullination of autoantigens), female sex (women affected 2–3 times more than men, suggesting hormonal contributions), obesity, and possible infectious triggers (EBV, Porphyromonas gingivalis, others). Seropositivity for rheumatoid factor or anti-CCP antibodies strongly predicts progressive structural damage and generally necessitates earlier, more aggressive DMARD therapy, whereas seronegative RA has more heterogeneous prognosis.

Ankylosing spondylitis (AS), psoriatic arthritis (PsA), enteropathic arthritis, and reactive arthritis share HLA-B27 association (present in 80–95% of AS patients, 60–80% of PsA patients) and involvement of axial skeleton and entheses (tendon/ligament insertions). HLA-B27 appears to drive disease through multiple mechanisms including altered peptide presentation favoring pro-inflammatory T cell responses, aberrant lipid antigen presentation through CD1d, and molecular mimicry with bacterial antigens. The prevalence of HLA-B27 positivity (~6–8% in European populations) explains disease prevalence, while additional genetic factors (IL-23R, ERAP1, others) and environmental factors (gastrointestinal infections triggering reactive arthritis, skin disease preceding or accompanying PsA) contribute. TNF-α plays a particularly important role in spondyloarthropathy pathogenesis, explaining exceptional efficacy of TNF inhibitors in these conditions, particularly for axial disease.

SLE is a systemic autoimmune disease of predominantly unknown etiology with strong female predominance (9:1 female:male), affecting up to 0.1% of the population with higher prevalence in African Americans and Hispanics than European Americans. Genetic factors include HLA associations (particularly HLA-DR2 and DR3), complement deficiencies (C1q, C4 deficiencies strongly associated with SLE), and single gene defects affecting immune tolerance (DNASE1L3, TNIP1, STAT1, others). Environmental triggers include UV exposure (exacerbating disease), drugs (procainamide, hydralazine, isoniazid causing drug-induced lupus), and possibly infections. The pathogenesis involves loss of tolerance to nuclear antigens (particularly dsDNA and nucleosomes), generation of pathogenic autoantibodies forming immune complexes, impaired clearance of apoptotic debris and immune complexes through Fc receptor and complement pathway deficiencies, and aberrant B and T cell activation. DMARDs particularly targeting B cells and type I interferon signaling prove efficacious in SLE.

Sjögren's syndrome, another B cell-predominant autoimmune condition, responds to rituximab and other B cell-targeted DMARDs. Vasculitis syndromes (ANCA-associated vasculitis treated with rituximab), inflammatory myositis, and systemic sclerosis have shown benefit with select DMARDs though with variable efficacy. Graft-versus-host disease (GVHD) after allogeneic stem cell transplantation, representing alloreactive T cell activation, often requires DMARDs for control.

The clinical presentation of DMARD-responsive diseases varies by specific condition but shares common patterns of inflammatory arthritis and systemic autoimmune manifestations. Understanding the physiology underlying each presentation guides diagnosis and treatment assessment:

The characteristic presentation of RA and other inflammatory arthropathies includes bilateral symmetric polyarticular joint pain, most pronounced in small joints of hands (PIP and MCP joints), wrists, and feet, with morning stiffness lasting >1 hour (often 2–3 hours) distinguishing inflammatory from mechanical arthritis. The stiffness reflects inflammatory exudate accumulating overnight in synovial spaces, with inflammatory mediators (TNF-α, IL-6, IL-1, others) stimulating type C nociceptors in synovial tissue. Upon movement and weight-bearing, improved synovial blood flow disperses inflammatory exudate and promotes lymphatic clearance, gradually improving stiffness throughout the day—morning stiffness duration therefore serves as a reliable disease activity measure. Pain results from inflammatory mediator stimulation of nociceptors, synovial distension from effusion, and mechanical factors including cartilage damage and periarticular structures inflammation.

Patients with active inflammatory arthritis frequently report significant fatigue disproportionate to disease severity, reflecting elevated systemic IL-6 and TNF-α with effects on central nervous system energy metabolism, sleep disruption from nocturnal pain, anemia of chronic disease from IL-6 mediated hepcidin upregulation and impaired erythropoiesis, and general cachexia from TNF-α effects on muscle protein metabolism. Constitutional symptoms including low-grade fevers (reflecting IL-6-driven prostaglandin E2 production and hypothalamic temperature set point elevation) and weight loss may accompany active disease.

Without DMARD therapy, progressive structural joint damage from synovial inflammation and pannus formation (granulation tissue eroding cartilage and bone) leads to progressive joint deformities and functional loss. Swan neck deformities (PIP hyperextension with DIP flexion), boutonniere deformities (PIP flexion with DIP hyperextension), ulnar deviation of fingers, and Z-thumb deformities exemplify irreversible mechanical changes reflecting both destructive inflammation and mechanical sequelae. Early DMARD therapy prevents these changes through inflammation suppression.

Examination reveals warm, swollen, tender joints with palpable synovial hypertrophy reflecting inflammatory hyperplasia and fluid accumulation. Tenderness on passive range of motion (pain with gentle joint flexion/extension) distinguishes inflammatory from mechanical